已发表论文

PIM-1激酶:三阴性乳腺癌的潜在生物标志物

 

Authors Chen J, Tang G

Received 18 April 2019

Accepted for publication 30 July 2019

Published 8 August 2019 Volume 2019:12 Pages 6267—6273

DOI https://doi.org/10.2147/OTT.S212752

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Shashank Kaushik (PT)

Peer reviewer comments 2

Editor who approved publication: Dr Sanjeev Srivastava

Abstract: Triple-negative breast cancer is associated with a poor prognosis, and effective biomarkers for targeted diagnosis and treatment are lacking. The tumorigenicity of the provirus integration site for Moloney murine leukemia virus 1 (PIM-1 ) gene has been studied for many years. However, its significance in breast cancer remains unclear. In this review we briefly summarized the physiological characteristics and regulation of PIM-1 kinase, and subsequently focused on the role of PIM-1 in tumors, especially breast cancer. Oncogene PIM-1  was found to be upregulated in breast cancer, especially in triple-negative breast cancer. Moreover, it is involved in tumorigenesis and the development of drug resistance, and linked to poor prognosis. A highly selective probe targeting PIM-1 for imaging has emerged, suggesting that PIM-1 may be a potential biomarker for the accurate diagnosis and targeted therapy of triple-negative breast cancer.
Keywords: triple-negative breast cancer, biomarker, PIM-1




Figure 1 PIM-1 gene and its transcripts and proteins.